Cargando…

First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19

Therapeutics for patients hospitalized with coronavirus disease 2019 (COVID‐19) are urgently needed during the pandemic. Bamlanivimab is a potent neutralizing monoclonal antibody that blocks severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) attachment and entry into human cells, which cou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Peter, Datta, Gourab, Grace Li, Ying, Chien, Jenny, Price, Karen, Chigutsa, Emmanuel, Brown‐Augsburger, Patricia, Poorbaugh, Josh, Fill, Jeffrey, Benschop, Robert J., Rouphael, Nadine, Kay, Ariel, Mulligan, Mark J., Saxena, Amit, Fischer, William A., Dougan, Michael, Klekotka, Paul, Nirula, Ajay, Benson, Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653186/ https://www.ncbi.nlm.nih.gov/pubmed/34455583 http://dx.doi.org/10.1002/cpt.2405

Ejemplares similares

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
por: Zhang, Lin, et al.
Publicado: (2021)

A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti‐SARS‐CoV‐2 Monoclonal Antibodies to Advance Bamlanivimab Into a First‐in‐Human Clinical Trial
por: Chigutsa, Emmanuel, et al.
Publicado: (2021)

The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination
por: Benschop, Robert J., et al.
Publicado: (2022)

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
por: Dougan, Michael, et al.
Publicado: (2021)

PK/PD modeling links accelerated resolution of COVID‐19‐related clinical symptoms to SARS‐CoV‐2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together
por: Ernest, C. Steven, et al.
Publicado: (2022)

Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection
por: Chigutsa, Emmanuel, et al.
Publicado: (2021)

Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab
por: Sims, Jonathan T., et al.
Publicado: (2022)

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
por: Chew, Kara W., et al.
Publicado: (2022)

Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
por: Chew, Kara W., et al.
Publicado: (2023)

COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine
por: Huhn, Gregory, et al.
Publicado: (2022)

Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial
por: Chew, Kara W., et al.
Publicado: (2021)

A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load
por: Dougan, Michael, et al.
Publicado: (2021)

BAMLANIVIMAB-INDUCED GUILLAIN-BARRÉ SYNDROME
por: PALAGUACHI, GLADYS, et al.
Publicado: (2021)

500. A Real-World Cohort Study of Bamlanivimab Versus Bamlanivimab-Etesevimab for Non-severe COVID-19
por: Monday, Lea, et al.
Publicado: (2021)

Bamlanivimab: Guillain-Barre syndrome: case report
Publicado: (2021)

Bamlanivimab: New-onset seizures: case report
Publicado: (2022)

146. Intact Sense of Taste and Smell During COVID-19 Infection Is Associated with Absence of of SARS-CoV-2 Spike Protein Antibody Responses within 3 Months of Symptomatic Illness
por: Wilson, James M, et al.
Publicado: (2021)

Bamlanivimab infusion experience at one academic emergency department
por: Yoo, Michael J., et al.
Publicado: (2022)

Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19
por: Destras, Grégory, et al.
Publicado: (2021)

Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses
por: Ramirez, Sydney I., et al.
Publicado: (2022)

Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process
por: Rubin, Emily B, et al.
Publicado: (2021)

Bamlanivimab for Mild to Moderate COVID-19 in Kidney Transplant Recipients
por: Jan, Muhammad Y., et al.
Publicado: (2021)

Real World Utilization of Bamlanivimab at a Rural Community Hospital
por: Leavitt, Rachael, et al.
Publicado: (2021)

542. Use of Bamlanivimab in Cancer Patients with Mild-to-Moderate COVID-19
por: Brock, Patricia, et al.
Publicado: (2021)

Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection
por: Bavaro, DF, et al.
Publicado: (2022)

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany
por: Jensen, Bjoern, et al.
Publicado: (2021)

Microneedle patch for immunization of immunocompromised hosts
por: Rouphael, Nadine G., et al.
Publicado: (2017)

Development of a Bamlanivimab Infusion Process in the Emergency Department for Outpatient COVID-19 Patients
por: Pham, Danny H., et al.
Publicado: (2021)

The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting
por: Corwin, Douglas S, et al.
Publicado: (2021)

506. Outpatient Bamlanivimab, Casirivimab and Imdevimab for COVID-19: Single Center Feasibility Analysis
por: Chundi, Vahini, et al.
Publicado: (2021)

Bamlanivimab: Gene mutation in COVID-19 infection and off label use: case report
Publicado: (2022)

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
por: Hoffmann, Markus, et al.
Publicado: (2021)

Impact of early versus late administration of bamlanivimab on readmissions in patients with high-risk COVID-19
por: Melton, James D., et al.
Publicado: (2021)

Efficacy of Bamlanivimab in Reducing Hospitalization and Mortality Rates in COVID-19 Patients in a Rural Community
por: Iqbal, Leena, et al.
Publicado: (2021)

Bamlanivimab: Transfusion-related acute lung injury following off label use: case report
Publicado: (2021)

Health System Success in Delivering Bamlanivimab Within Post-acute and Long-Term Care Facilities
por: Walker, Victoria L., et al.
Publicado: (2022)

Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis
por: Zuo, Ling, et al.
Publicado: (2022)

Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern
por: Falcone, Marco, et al.
Publicado: (2021)

Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study
por: Kumar, Rebecca N, et al.
Publicado: (2021)

A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2
por: Nathan, Ramesh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oc45c1v4jr01qmnrmpmb4ai95b